Monitoring Copper in Wilson's Disease

Advances in Clinical Chemistry

Volumn 50, Issue , 2010, Pages 151-163

  Walshe, J M ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER;

BLOOD; HUMAN; METABOLISM; REVIEW; WILSON DISEASE;

COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS;

EID: 77954067057     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)50008-8     Document Type: Chapter

References (32)

1. [1] Mak, C.M., Lam, C.W., Diagnosis of Wilson's disease: a comprehensive review. Crit. Rev. Clin. Lab. Sci. 45 (2008), 263–290.
2. [2] Scheinberg, I.H., Sternlieb, I., Wilson's disease. Smith, L.H., (eds.) Major Problems in Internal Medicine, 23, 1984, WB Saunders Co, Philadelphia, PA.
3. [3] Walshe, J.M., Wilson's disease: the importance of measuring caeruloplasmin serum ceruloplasmin non-immunologically. Ann. Clin. Biochem. 40 (2003), 115–121.
4. [4] Sternlieb, I., Morell, A.G., Bauer, C.D., Combes, B., DeBobes-Sternberg, S., Scheinberg, I.H., Detection of the heterozygous carrier of the Wilson's disease gene. J. Clin. Invest. 40 (1961), 707–715.
5. [5] Sussman, W., Scheinberg, I.H., Disappearance of Kayser–Fleischer rings. Arch. Ophthalmol. 82 (1969), 738–741.
6. [6] Cairns, J.E., Walshe, J.M., The Kayser–Fleischer ring. Trans. Ophthalmol. Soc. U.K. 90 (1970), 187–190.
7. [7] Cumings, J.N., The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 71 (1948), 410–415.
8. [8] Sternlieb, I., Scheinberg, I.H., Penicillamine therapy in hepatolenticular degeneration. JAMA 189 (1980), 748–754.
9. [9] Marecek, Z., Heyrovsky, A., Volek, V., The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease. Acta Hepatogastroenterol. 22 (1975), 292–296.
10. [10] Scheinberg, I.H., Sternlieb, I., Schilsky, M., Stockert, R.J., Penicillamine may detoxify copper in Wilson's disease. Lancet, 330, 1987, 95.
11. [11] Gibbs, K., Walshe, J.M., Liver copper concentration in Wilson's disease: effect of treatment with ‘anti-copper’ agents. J. Gastroenterol. Hepatol. 5 (1990), 420–424.
12. [12] Walshe, J.M., Penicillamine. A new oral therapy for Wilson's disease. Am. J. Med. 21 (1956), 487–495.
13. [13] Schouwink, G., De hepatocerebrale degenerate, met een onderzoek naar de zinkstofwisseling. MD Thesis, Amsterdam State University, 1961, Van der Wiel, Arnhem.
14. [14] Walshe, J.M., Management of penicillamine nephropathy in Wilson's disease: a new chelating agent. Lancet 294 (1969), 1041–1042.
15. [15] Starzl, T.E., Iwatsuki, S., Van Theil, D.H., Gartner, C.J., Zitelli, B.J., Malatack, J.J., et al. Evolution of liver transplantation. Hepatology 2 (1982), 614–636.
16. [16] Walshe, J.M., Copper: its role in the pathogenesis of liver disease. Sem. Liver Dis. 4 (1984), 252–263.
17. [17] Williams, F.J., Walshe, J.M., Wilson's disease. An analysis of the cranial computerised tomography appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain 104 (1981), 735–752.
18. [18] King, A.D., Walshe, J.M., Kendall, B.E., Chinn, R.J.S., Pasley, M.N., Wilkinson, D., et al. Cranial MR Imaging in Wilson's disease. Am. J. Roentgenol. 167 (1996), 1579–1584.
19. [19] Watten, R.H., Jun-bi, Tu., Blackwell, R.Q., Tsung Yung Hou, B.S., Contribution of copper balance studies to investigation and management of Wilson's disease. Birth Defects Orig. Artic. Ser. 4 (1968), 35–40.
20. [20] Gibbs, K., Walshe, J.M., A study of the caeruloplasmin concentration found in 75 patients with Wilson's disease, their kinships and various control groups. Q. J. Med. 48 (1979), 447–463.
21. [21] Walshe, J.M., Filterable and non-filterable serum copper (1) The action of penicillamine. Clin. Sci. 25 (1963), 405–411.
22. [22] Walshe, J.M., Yealland, M., Not Wilson's disease: a review of misdiagnosed cases. Q. J. Med. 88 (1995), 55–59.
23. [23] Roberts, E.A., Schilsky, M.I., Diagnosis and treatment of Wilson's disease. An update. Hepatology 47 (2008), 2089–2111.
24. [24] Walshe, J.M., Endogenous copper clearance in Wilson's disease: a study of the mode of action of penicillamine. Clin. Sci. 26 (1963), 461–469.
25. [25] Walshe, J.M., Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylenetetramine dihydrochloride. Q. J. Med. 42 (1973), 441–452.
26. 64Cu) in Wilson's disease: dynamics of copper transport. Q. J. Med. 29 (1965), 575–581.
27. [27] Van den Hameer, C.J.A., Hoogenraad, T.U., Kroon, J.J., Diagnosis and monitoring of Wilson's disease. Czlonkowska, A., Van den Hamer, C.J.A., (eds.), Proceedings of the 5th Symposium on Wilson's disease, Madralin, Poland, 1991, Technical University, Delft, The Netherlands, 21–27.
28. [28] Siegemund, R., Gunther, K., Lossner, J., Bachmann, H., Oral 64copper test in the therapeutic management. Czlonkowska, A., Van den Hamer, C.J.A., (eds.), Proceedings of the 5th Symposium on Wilson's disease, Madralin, Poland, 1991, Technical University, Delft, The Netherlands, 71–78.
29. [29] Bachmann, H., Lossner, J., Kihn, H.-J., Siegemund, R., Lossner, A., Diagnostic strategies in Wilson's disease. Czlonkowska, A., Van den Hamer, C.J.A., (eds.), Proceedings of the 5th Symposium on Wilson's disease, Madralin, Poland, 1991, Technical University, Delft, The Netherlands, 79–86.
30. [30] Siegemund, R., Gunther, K., Biesold, D., Bachmann, H., Lossner, J., The radiocopper test—the experience of 20 years. Czlonkowska, A., Van den Hamer, C.J.A., (eds.), Proceedings of the 5th Symposium on Wilson's disease, Madralin, Poland, 1991, Technical University, Delft, The Netherlands, 87–94.
31. 64Cu) in Wilson's disease and various control groups. Q. J. Med. 46 (1977), 445–462.
32. [31] Gibbs, K., Hanka, R., Walshe, J.M., The urinary excretion of radiocopper in presymptomatic and symptomatic Wilson's disease, heterozygotes and controls. Its significance in diagnosis and management. Q. J. Med. 47 (1978), 349–364.